Please ensure Javascript is enabled for purposes of website accessibility

Why Bluebird Bio Stock Is Plunging Today

By Keith Speights – Dec 20, 2021 at 11:15AM

Key Points

  • The FDA's partial hold on clinical studies of lovo-cel, its sickle cell treatment, applies only to patients under age 18.
  • Bluebird hopes to quickly address the FDA's concerns and continues to enroll patients 18 and up.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA placed a partial clinical hold on Bluebird's clinical studies of lovo-cel.

What happened

Shares of Bluebird Bio (BLUE 1.27%) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its clinical testing of lovo-cel in treating sickle cell disease on partial clinical hold. This partial clinical hold applies only to patients under age 18.

The FDA's decision is connected with Bluebird's ongoing investigation related to one adolescent patient who experienced persistent non-transfusion-dependent anemia after being treated with lovo-cel. Bluebird said that the patient is "clinically well" and added that there has been "no evidence of malignancy or clonal predominance."

A healthcare professional holding a hand up in a halting gesture.

Image source: Getty Images.

So what

It's not surprising for a biotech stock to sink on news of an FDA clinical hold. In this case, though, Bluebird seems to expect that the partial clinical hold will only be temporary. Bluebird's chief medical officer, Richard Colvin, said that the company is working with the FDA to "understand and address their concerns."

Bluebird isn't sure at this point how this partial clinical hold might impact its timing for the filing for FDA approval of lovo-cel. The company has previously stated that it hoped to file a Biologics License Application for the gene therapy in the first quarter of 2023.

Now what

Bluebird expects to receive written questions from the FDA early next year about the partial clinical hold for lovo-cel. The company plans to respond to those questions as quickly as possible in hopes of having the partial hold lifted. In the meantime, Bluebird continues to enroll and dose patients ages 18 and older in its clinical studies evaluating lovo-cel.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Bluebird Bio. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.